TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung

Cancer Letters

Volumn 124, Issue 1, 1998, Pages 73-78

  Di Loreto, Carla ^a   Puglisi, Fabio ^a   Di Lauro, Vincenzo ^a   Damante, Giuseppe ^a   Beltrami, Carlo Alberto ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Immunohistochemistry; Lung adenocarcinoma; Pleural malignant mesothelioma; TTF 1 protein

Indexed keywords

ANTISERUM; PEROXIDASE; TRANSCRIPTION FACTOR;

ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; EPITHELIUM CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG; LUNG ADENOCARCINOMA; LUNG BIOPSY; MALIGNANT MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID GLAND;

ADENOCARCINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MESOTHELIOMA; NUCLEAR PROTEINS; PLEURAL NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032512614     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(97)00466-7     Document Type: Article

References (33)

1. Attanoos R.L., Gibbs A.R. Pathology of malignant mesothelioma. Histopathology. 30:1997;403-418.
2. Brown R.W., Clark G.M., Tandon A.T., Allred C. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesotheliomas from pulmonary adenocarcinoma. Hum. Pathol. 24:1993;347-354.
3. Burns T.R., Greenberg D., Mace M.L., Johnson E.H. Ultrastructural diagnosis of epithelial malignant mesothelioma. Cancer. 56:1985;2036-2040.
4. Leong A.S.-Y.M., Stevens M.W., Mukherjee T.M. Malignant mesothelioma: cytologic diagnosis with histologic, immunohistochemical, and ultrastructural correlation. Semin. Diagn. Pathol. 9:1992;141-150.
5. Roggli V.L., Kolbeck J., Sanfilippo F. Pathology of human mesothelioma. Aetiology and diagnostic considerations. Pathol. Annu. 22:1987;91-131.
6. Battifora H., Kopinski M.I. Distinction of mesothelioma from adenocarcinoma. An immunohistochemical approach. Cancer. 55:1985;1679-1685.
7. Szpak C.A., Johnston W.W., Roggli V.et al. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). Am. J. Pathol. 122:1986;252-260.
8. Sheibani K., Battifora H., Burke J.S. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu-M1 antigen. Am. J. Pathol. 123:1986;212-219.
9. Otis C.N., Carter D., Cole S., Battifora H. Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma. A bi-institutional study of 47 cases. Am. J. Surg. Pathol. 11:1987;445-456.
10. Ordonez N.G. The immunohistochemical diagnosis of mesothelioma. Am. J. Surg. Pathol. 13:1989;276-291.
11. Wirth P.R., Legier J., Wright G.L. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma. Cancer. 67:1991;655-662.
12. Soosay G.N., Griffiths M., Papadaki L., Happerfield L., Bobrow L. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation. J. Pathol. 163:1991;299-305.
13. Sheibani K., Esteban J.M., Bailey A., Battifora H., Weiss L.M. Immunopathologic and molecular studies as an aid to diagnosis of malignant mesothelioma. Hum. Pathol. 23:1992;107-116.
14. Weiss L.M., Battifora H. The search for the optimal immunohistochemical panel for the diagnosis of malignant mesothelioma. Hum. Pathol. 24:1993;345-346.
15. Dejmek A., Hjerpe A. Immunohistochemical reactivity in mesothelioma and adenocarcinoma: a stepwise logistic regression analysis. Acta Pathol. Microbiol. Immunol. Scand. 102:1994;255-264.
16. Attanoos R.L., Goddard H., Gibbs A.R. Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HMBE-1 and their use in the diagnosis of mesothelioma. Histopathology. 29:1996;209-215.
17. Doglioni C., Dei Tos A.P., Laurino L.et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am. J. Surg. Pathol. 20:1996;1037-1046.
18. Lonigro R., De Felice M., Biffali E.et al. Expression of thyroid transcription factor 1 gene can be regulated at the transcriptional and posttranscriptional levels. Cell Growth Diff. 7:1996;251-261.
19. Lazzaro D., Price M., De Felice M., Di Lauro R. The transcription factor TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of fetal brain. Development. 113:1991;1093-1104.
20. Ikeda K., Clark J.C., Shaw-White J.R., Stahlman M.T., Boutell C.J., Whitsett J.A. Gene structure and expression of human thyroid transcription factor-1 in respiratory epithelial cells. J. Biol. Chem. 270:1995;8108-8114.
21. Bohinski R.J., Di Lauro R., Whitsett J.A. The lung-specific protein B promoter is a target for thyroid transcription factor 1 and hepatocyte nuclear factor 3, indicating common factors for organ specific gene expression along the foregut. Mol. Cell. Biol. 14:1994;5671-5681.
22. H. Battifora, W.T.E. Mc Caughey, Diffuse malignant mesothelioma, in: J. Rosai, L.H. Sobin (Eds.), Tumors of Serosal Membranes, Atlas of Tumor Pathology, third series, Armed Forces Institute of Pathology, Washington, DC, 1995, pp. 17-88.
23. Donna A., Betta P.G. Differentiation towards cartilage and bone in a primary tumor of the pleura. Further evidence in support of the concept of mesodermoma. Histopathology. 10:1986;101-108.
24. Fabbro D., Di Loreto C., Stamerra O., Beltrami C.A., Lo Nigro R., Damante G. TTF-1 gene expression in human lung tumours. Eur. J. Cancer. 32A:1996;512-517.
25. Fabbro D., Di Loreto C., Beltrami C.A., Belfiore A., Di Lauro R., Damante G. Tissue-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasm. Cancer Res. 54:1994;4744-4749.
26. Di Loreto C., Di Lauro V., Puglisi F., Damante G., Fabbro D., Beltrami C.A. Immunocytochemical expression of tissue specific transcription factor-1 in lung carcinoma. J. Clin. Pathol. 50:1997;30-33.
27. Bejarano P.A., Baugman R.P., Biddinger P.W.et al. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod. Pathol. 9:1996;445-452.
28. World Health Organization The World Health Organization histological typing of lung tumors. Am. J. Clin. Pathol. 77:1982;123-136.
29. Roggli V.L., Kolbeck J., Sanfilippo F., Shelburne J.D. Pathology of human mesothelioma. Etiologic and diagnostic considerations. Part 2. Pathol. Annu. 22:1987;91-131.
30. de Klerk N.H., Musk A.W., Eccles J.L., Hansen J., Hobbs M.S. Exposure to crocidolite and the incidence of different histological types of lung cancer. Occup. Environ. Med. 53:1996;157-159.
31. Wharhol M.J., Hichey W.F., Corson J.M. Malignant mesothelioma, ultrastructural distinction from adenocarcinoma. Am. J. Surg. Pathol. 6:1982;307-314.
32. Coleman M., Henderson D.W., Mukherjee T.M. The ultrastructural pathology of malignant pleural mesothelioma. Pathol. Annu. 24:1989;303-353.
33. Clayton F. Bronchioloalveolar carcinomas. Cell types, pattern of growth and prognostic correlates. Cancer. 57:1986;1555-1564.